| Age (year) | Post-PCV7 period | Three most prevalent serotypes | Post-higher valent PCV periods | Three most prevalent serotypes | ||
---|---|---|---|---|---|---|---|
Year | Among all IPD, % | Year | Among all IPD, % | ||||
Countries in which only PCV13 used | |||||||
Belgium [11] | <5 | 2010 | 73 | 19A, 1, 7Â F | 2013 | 36 | 1, 12Â F, 24Â F |
France [20] | <2 | 2009 | 71 | 19A, 7Â F, 1 | 2012 | 24 | 24Â F, 12Â F, 15B/C |
Italy [24] | <5 | 2011 | 64 | 1, 19A, 22Â F | 2014 | 37 | 19A, 1, 24Â F |
Norway [25] | <5 | 2010 | 61 | 19A, 1, 7Â F | 2012 | 26 | 1, 15B/C |
Switzerland [29] | <2 | 2010–2011 | 68 | 3, 19A, 7 F | 2012 | 53 | 3, 23 (not 23 F), 19 F |
UK [31] | <5 | 2008–2010 | 68 | 7 F, 19A, 1 | 2013–2014 | 15 | 24 F, 22 F, 33 F |
Countries in which only PCV10 used | |||||||
<5 | 2009 | 73 | 3, 14, 18C | 2013 | 93 | 19A, 7Â F, 23Â F | |
Finland [39] | <5 | 2010 | 92 | 14, 6B, 19Â F | 2014 | 70 | 19A, 3, 7Â F, 23A |
Countries in which both PCV13 and PCV10 used | |||||||
Germanya [44] | <16 | 2008–2009 | 56 | 7 F, 1, 18Cb | 2012–2013 | 12 | 7 F, 10A, 19Ac |
Sweden [45] | <2 | 2009 | 84 | 22Â F, 7Â F, 3, 19A | 2012 | 47 | 33Â F, 11 |